VOYA Investment Management
RARE icon

VOYA Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

VOYA Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,934
Closed -$458K – 2423
2025
Q4 		$458K Sell
19,934
-679
-3% -$22.3K ﹤0.01% 1790
2025
Q3 		$620K Sell
20,613
-29,303
-59% -$879K ﹤0.01% 1665
2025
Q2 		$1.81M Sell
49,916
-13,280
-21% -$479K ﹤0.01% 1345
2025
Q1 		$2.29M Sell
63,196
-9,125
-13% -$380K ﹤0.01% 1248
2024
Q4 		$3.04M Sell
72,321
-89,772
-55% -$4.45M ﹤0.01% 1134
2024
Q3 		$9M Buy
162,093
+75,215
+87% +$3.83M 0.01% 811
2024
Q2 		$3.57M Sell
86,878
-15,588
-15% -$666K ﹤0.01% 1135
2024
Q1 		$4.78M Sell
102,466
-66,218
-39% -$3.12M ﹤0.01% 1027
2023
Q4 		$8.07M Buy
168,684
+93,286
+124% +$3.62M 0.01% 822
2023
Q3 		$2.69M Sell
75,398
-998
-1% -$39.5K ﹤0.01% 1223
2023
Q2 		$3.52M Buy
76,396
+19,219
+34% +$891K ﹤0.01% 1140
2023
Q1 		$2.29M Sell
57,177
-636
-1% -$27.3K ﹤0.01% 1302
2022
Q4 		$2.68M Buy
57,813
+6
+0% +$236 ﹤0.01% 1224
2022
Q3 		$2.39M Buy
57,807
+33,851
+141% +$1.74M ﹤0.01% 1247
2022
Q2 		$1.43M Sell
23,956
-2,019
-8% -$124K ﹤0.01% 1240
2022
Q1 		$1.89M Sell
25,975
-27,099
-51% -$1.89M ﹤0.01% 1140
2021
Q4 		$4.46M Buy
53,074
+35,305
+199% +$2.87M 0.01% 885
2021
Q3 		$1.6M Sell
17,769
-323
-2% -$29.2K ﹤0.01% 1290
2021
Q2 		$1.73M Sell
18,092
-9,772
-35% -$1.02M ﹤0.01% 1281
2021
Q1 		$3.17M Buy
27,864
+896
+3% +$122K 0.01% 993
2020
Q4 		$3.73M Buy
26,968
+7,283
+37% +$864K 0.01% 910
2020
Q3 		$1.62M Hold
19,685
– – ﹤0.01% 1099
2020
Q2 		$1.54M Sell
19,685
-7,381
-27% -$489K ﹤0.01% 1108
2020
Q1 		$1.2M Sell
27,066
-255,810
-90% -$13.3M ﹤0.01% 1147
2019
Q4 		$12.1M Buy
282,876
+15,042
+6% +$621K 0.03% 549
2019
Q3 		$11.5M Sell
267,834
-2,642
-1% -$144K 0.03% 563
2019
Q2 		$17.2M Sell
270,476
-116,837
-30% -$7.44M 0.04% 431
2019
Q1 		$26.9M Buy
387,313
+148,485
+62% +$8.48M 0.06% 291
2018
Q4 		$10.4M Sell
238,828
-112,780
-32% -$6.16M 0.03% 530
2018
Q3 		$26.8M Sell
351,608
-75,180
-18% -$6.11M 0.06% 348
2018
Q2 		$32.8M Buy
426,788
+408,403
+2,221% +$26.4M 0.07% 302
2018
Q1 		$937K Buy
18,385
+825
+5% +$41.5K ﹤0.01% 1421
2017
Q4 		$814K Sell
17,560
-698
-4% -$34.2K ﹤0.01% 1545
2017
Q3 		$972K Sell
18,258
-149,527
-89% -$8.86M ﹤0.01% 1456
2017
Q2 		$10.4M Buy
167,785
+6,816
+4% +$411K 0.02% 598
2017
Q1 		$10.9M Buy
160,969
+17,949
+13% +$1.37M 0.03% 576
2016
Q4 		$10.1M Sell
143,020
-47,574
-25% -$3.38M 0.02% 583
2016
Q3 		$13.5K Buy
190,594
+42,531
+29% +$2.71M 0.03% 474
2016
Q2 		$7.24M Buy
148,063
+10,269
+7% +$664K 0.02% 673
2016
Q1 		$8.72M Sell
137,794
-74,130
-35% -$4.85M 0.02% 582
2015
Q4 		$23.8M Buy
211,924
+195,410
+1,183% +$19.5M 0.06% 302
2015
Q3 		$1.59M Sell
16,514
-1,240
-7% -$142K ﹤0.01% 1084
2015
Q2 		$1.82M Buy
+17,754
New +$1.38M ﹤0.01% 1112

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VOYA Investment Management's RARE Position: Q1 2026 in Review

VOYA Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 19,934 shares — an estimated $458K sold.

VOYA Investment Management first reported a position in RARE in Q2 2015 and held it in 43 quarters. The position peaked at $32.8M in Q2 2018. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • VOYA Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • VOYA Investment Management sold 19,934 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $458K.
  • VOYA Investment Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 43 quarters.
  • VOYA Investment Management's Ultragenyx Pharmaceutical position peaked at $32.8M in Q2 2018.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on VOYA Investment Management's 13F filing for Q1 2026, filed 12 May 2026.